Why We’re Bringing AI Neurosurgery to Oman

Every minute counts when a patient arrives at an emergency department with a suspected brain hemorrhage. In that race, AI-assisted triage is no longer a luxury — it is becoming standard of care.

At 334 Aqua Med Soft, we have spent the last four years building exactly that: a surgical-assistance platform whose ICH detection module reads CT scans at 95% accuracy, trained on close to a million medical images. The system is part of a national neurosurgery training curriculum, holds official efficacy approval from a national health ministry, and has completed its first commercial sale — with a purchase request for twenty more devices on record.

Now we are looking at the Gulf — and specifically at Oman.

Oman’s Ministry of Health has announced an ambitious and concrete goal: raise locally manufactured health products from 9% to 30% of the market within three years. The Future Fund Oman has dedicated RO 50 million to healthcare investment, spanning medical technology and digital health. Hospitals are modernizing, insurance coverage is expanding, and the country is actively courting companies that can help build a domestic medical industry.

For an AI company with a clinically validated product, that is a rare alignment of timing and need.

We are beginning conversations with Omani hospitals, regulators and investors about three things: a clinical pilot in neurosurgery and emergency settings, local assembly toward the 30% localization goal, and the partnerships that will fund our ISO 13485 completion and Canadian regulatory roadmap.

Nothing about this journey has been conventional — from our founding in Winnipeg to clinical validation abroad and now the Gulf. But if there is one lesson we have learned, it is this: clinical credibility opens doors that marketing never will.

If you work in Oman’s healthcare or investment ecosystem and see a fit, we would love to talk.

— Saeed Bayat, Co-founder & CEO

Scroll to Top